according to the Hazardous Products Regulations



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.1	09/30/2023	717974-00016	Date of first issue: 06/01/2016

SECTION 1. IDENTIFICATION

Product name	:	Olmesartan Formulation
Other means of identification	:	No data available

Manufacturer or supplier's details

Company name of supplier	:	Organon & Co.
Address	:	30 Hudson Street, 33nd floor
		Jersey City, New Jersey, U.S.A 07302
Telephone	:	1-551-430-6000
Emergency telephone	:	1-215-631-6999
E-mail address	:	EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use	:	Pharmaceutical
Restrictions on use	: 1	Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS clas	ssificatio	n in accordanc	e with the	e Hazardous	Products	Regulations

Reproductive toxicity	:	Category 1A

GHS label elements

GHS label elements Hazard pictograms	:		
Signal Word	:	Danger	
Hazard Statements	:	H360D May damage the unborn child.	
Precautionary Statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves, protective clothing, eye protection and face protection.	
		Response: P308 + P313 IF exposed or concerned: Get medical attention.	
		Storage: P405 Store locked up.	
		Disposal: P501 Dispose of contents and container to an approved waste disposal plant.	

according to the Hazardous Products Regulations



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.1	09/30/2023	717974-00016	Date of first issue: 06/01/2016

Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Olmesartan	No data availa- ble	144689-63-4	>= 5 - < 10 *
Cellulose	No data availa- ble	9004-34-6	>= 5 - < 10 *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	
Protection of first-aiders	:	
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray
		Alcohol-resistant foam
		Carbon dioxide (CO2)
		Dry chemical

according to the Hazardous Products Regulations



Olmesartan Formulation

Version 3.1	Revision Date: 09/30/2023		9S Number: 7974-00016	Date of last issue: 04/04/2023 Date of first issue: 06/01/2016
mec Spe	Unsuitable extinguishing media Specific hazards during fire fighting		concentrations, ar potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a losion hazard. bustion products may be a hazard to health.
Haz ucts	ardous combustion prod-	:	Carbon oxides	
Spe ods	Specific extinguishing meth- ods		cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	cial protective equipment ire-fighters	:	Evacuate area. In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.
SECTIO	N 6. ACCIDENTAL RELE	ASI	EMEASURES	
tive	sonal precautions, protec- equipment and emer- cy procedures	:		ective equipment. Ing advice (see section 7) and personal ent recommendations (see section 8).
Env	ironmental precautions	:	Retain and dispos	akage or spillage if safe to do so. e of contaminated wash water. hould be advised if significant spillages
	hods and materials for ainment and cleaning up	:	container for disper Avoid dispersal of with compressed Dust deposits sho surfaces, as these released into the a Local or national r disposal of this ma employed in the c determine which r Sections 13 and 1	dust in the air (i.e., clearing dust surfaces

SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion.
		Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.

according to the Hazardous Products Regulations



Olmesartan Formulation

Version 3.1	Revision Date: 09/30/2023	SDS Number: 717974-00016	Date of last issue: 04/04/2023 Date of first issue: 06/01/2016
Advice on safe handling		Do not breath Do not swallo Avoid contact Handle in acc practice, base assessment Keep containe Keep containe Keep away fre Take precauti	w.
Co	nditions for safe storage	Store locked Keep tightly c	losed.
Ma	terials to avoid	: Do not store v Strong oxidizi	substances and mixtures

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis
		exposure)	concentration	
Olmesartan	144689-63-4	TWA	30 µg/m3 (OEB 3)	Internal
		Wipe limit	300 µg/100 cm ²	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total	10 mg/m ³	CA BC OEL
		dust)		
		TWA (respir- able dust	3 mg/m³	CA BC OEL
		fraction)		
		TWAEV (to-	10 mg/m ³	CA QC OEL
		tal dust)		
		TWA	10 mg/m ³	ACGIH

Engineering measures

: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

according to the Hazardous Products Regulations



Olmesartan Formulation

Version 3.1	Revision Date: 09/30/2023	SDS Number: 717974-00016	Date of last issue: 04/04/2023 Date of first issue: 06/01/2016
Pers	sonal protective equip	ment	
Resp	piratory protection	exposure ass	ocal exhaust ventilation is not available or sessment demonstrates exposures outside the of guidelines, use respiratory protection.
	ilter type d protection	: Particulates t	
Ν	laterial	: Chemical-res	sistant gloves
	emarks protection	If the work er mists or aero Wear a faces	uble gloving. glasses with side shields or goggles. hvironment or activity involves dusty conditions, sols, wear the appropriate goggles. shield or other full face protection if there is a direct contact to the face with dusts, mists, or
Skin	and body protection	: Work uniform Additional bo task being pe disposable so	n or laboratory coat. dy garments should be used based upon the erformed (e.g., sleevelets, apron, gauntlets, uits) to avoid exposed skin surfaces. ate degowning techniques to remove potentially d clothing.
Hygi	ene measures	: If exposure to eye flushing s working place When using o Wash contan The effective engineering o appropriate o industrial hyg	o chemical is likely during typical use, provide systems and safety showers close to the

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available

according to the Hazardous Products Regulations



Olmesartan Formulation

Vers 3.1	sion	Revision Date: 09/30/2023	-	S Number: 974-00016	Date of last issue: 04/04/2023 Date of first issue: 06/01/2016
	Flamma	ability (solid, gas)	:	May form explosi handling or other	ve dust-air mixture during processing, means.
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Vapor p	oressure	:	No data available	
	Relative	e vapor density	:	No data available	
	Relative	e density	:	No data available	
	Density	,	:	No data available	
	Solubili Wat	ty(ies) er solubility	:	No data available	
	Partitio octanol	n coefficient: n-	:	No data available	
		nition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	Viscosi Visc	ty cosity, kinematic	:	No data available	
	Explosi	ve properties	:	Not explosive	
	Oxidiziı	ng properties	:	The substance or	mixture is not classified as oxidizing.
	Molecu	lar weight	:	No data available	
	Particle	size	:	No data available	

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials Hazardous decomposition	:	Oxidizing agents No hazardous decomposition products are known.

according to the Hazardous Products Regulations



Olmesartan Formulation

ersion 1	Revision Date: 09/30/2023	SDS Number: 717974-00016		Date of last issue: 04/04/2023 Date of first issue: 06/01/2016
produ	cts			
CTION	11. TOXICOLOGICA	L INFC	RMATION	
Inhala Skin o Ingest	contact	es of e	exposure	
	e toxicity assified based on ava	ailable i	nformation.	
Produ	<u>ict:</u>			
Acute	oral toxicity	:	Acute toxicity e Method: Calcu	estimate: > 2,000 mg/kg lation method
Comp	oonents:			
Olme	sartan:			
Acute	oral toxicity	:	LD50 (Rat): > 2	2,000 mg/kg
			LD50 (Mouse)	: > 2,000 mg/kg
			LD50 (Dog): >	1,500 mg/kg
Acute	inhalation toxicity	:	Remarks: No o	lata available
Acute	dermal toxicity	:	Remarks: No o	lata available
Cellu	lose:			
Acute	oral toxicity	:	LD50 (Rat): >	5,000 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > Exposure time Test atmosphe	:4 h
Acute	dermal toxicity	:	LD50 (Rabbit):	> 2,000 mg/kg
	corrosion/irritation assified based on ava	ailable i	nformation.	
Comp	oonents:			
Olme	sartan:			
Rema	rks	:	No data availa	ble

according to the Hazardous Products Regulations



Olmesartan Formulation

rsion	Revision Date: 09/30/2023	-	DS Number: 7974-00016	Date of last issue: 04/04/2023 Date of first issue: 06/01/2016
<u>Com</u>	ponents:			
Olme	esartan:			
Speci		:	Rabbit	
Resu Metho		:	Moderate eye Draize Test	irritation
Metho	Ju	•	Dialze Test	
Resp	iratory or skin sensit	tizatio	on	
-	sensitization lassified based on ava	ilable	information.	
Resp	iratory sensitization			
Not c	lassified based on ava	ilable	information.	
<u>Com</u>	ponents:			
Olme	esartan:			
	es of exposure	:	Skin contact	
Rema	arks	:	No data availa	ble
Not c	n cell mutagenicity lassified based on ava ponents:	ilable	information.	
	sartan:			
	toxicity in vitro	:	Test Type: Bac Result: negativ	cterial reverse mutation assay (AMES) /e
			Test Type: Mu Result: negativ	tagenicity (in vitro mammalian cytogenetic test /e
			••	romosome aberration test in vitro Chinese hamster lung cells e
			Test Type: Mo Result: negativ	use Lymphoma /e
Geno	toxicity in vivo	:	Test Type: Mic Species: Mous Cell type: Bon Application Ro Result: negativ	e marrow ute: Oral
	i cell mutagenicity - ssment	:	Weight of evid cell mutagen.	ence does not support classification as a germ
Cellu	lose.			
UCIIU				

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative

according to the Hazardous Products Regulations



Olmesartan Formulation

ersion .1	Revision Date: 09/30/2023	SDS Number: 717974-00016	Date of last issue: 04/04/2023 Date of first issue: 06/01/2016				
		Test Type: Ir Result: nega	n vitro mammalian cell gene mutation test tive				
Geno	toxicity in vivo	cytogenetic a Species: Mo Application F	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative				
	nogenicity						
	assified based on ava	illable information.					
Comp	oonents:						
	sartan:						
Speci		: Rat					
	ation Route	: Oral : 2 Years					
Resul		: negative					
Speci	es	: Mouse					
Applic	ation Route	: Oral					
	sure time	: 6 Months					
Resul	t	: negative					
Cellu	lose:						
Speci		: Rat					
	ation Route	: Ingestion : 72 weeks					
Resul		: negative					
Repro	oductive toxicity						
May c	lamage the unborn ch	ild.					
<u>Comp</u>	oonents:						
Olme	sartan:						
Effect	s on fertility	: Test Type: F					
		Species: Rat Application F					
		Fertility: NOA	AEL: 1,000 mg/kg body weight				
		Result: No e	ffects on fertility.				
Effect	s on fetal developmer						
		Species: Rat Application F					
			milligram per kilogram				
			eratogenic effects.				
		Test Type: D	evelopment				
		Species: Ral	obit				
		Application F	Route: Oral gram per kilogram				
			granı per kilogranı				

according to the Hazardous Products Regulations



Olmesartan Formulation

ersion .1	Revision Date: 09/30/2023		0S Number: 7974-00016	Date of last issue: 04/04/2023 Date of first issue: 06/01/2016
			Result: No terato	genic effects.
			Symptoms: Malfo weight	
Reprod sessme	uctive toxicity - As- ent	:	Positive evidence human epidemiol	of adverse effects on development from ogical studies.
Cellulo	se:			
Effects	on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study :: Ingestion
Effects	on fetal development	:	Test Type: Fertilit Species: Rat Application Route Result: negative	y/early embryonic development :: Ingestion
	single exposure	b .1.5		
	ssified based on availa repeated exposure	aidi	information.	
	ssified based on availa	ble	information.	
Repeat	ed dose toxicity			
Compo	onents:			
Olmesa	artan:			
Species NOAEL			Rat 2,000 mg/kg	
Applica	tion Route	:	Oral	
Exposu Remarl		:	24 Months No significant adv	verse effects were reported
Cellulo	se:			
Species		:	Rat	
NOAEL Applica	- tion Route		>= 9,000 mg/kg Ingestion	
Exposu		:	90 Days	
Aspira	tion toxicity			
-	ssified based on availa	ble	information.	

according to the Hazardous Products Regulations



Olmesartan Formulation

rsion	Revision Date: 09/30/2023	SDS Number: 717974-00016	Date of last issue: 04/04/2023 Date of first issue: 06/01/2016
Exper	ience with human ex	posure	
Comp	oonents:		
Olme	sartan:		
Eye co Ingest	ontact	: Symptoms: Ey : Symptoms: hy	
ingesi	.011	Remarks: May	cause harm to the unborn child.
		Based on Hum	an Evidence
CTION	12. ECOLOGICAL INI	FORMATION	
Ecoto	oxicity		
Comp	oonents:		
Cellul	ose:		
Toxici	ty to fish	Exposure time	latipes (Japanese medaka)): > 100 mg/l : 48 h ed on data from similar materials
Persis	stence and degradab	ility	
<u>Comp</u>	oonents:		
Cellul	ose:		
Biode	gradability	: Result: Readily	/ biodegradable.
Bioac	cumulative potential		
No da	ta available		
	ity in soil		
	ta available		
Other	adverse effects ta available		

Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

according to the Hazardous Products Regulations



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.1	09/30/2023	717974-00016	Date of first issue: 06/01/2016

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product ar	e	re	p	orte	ed i	in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH CA AB OEL	:	USA. ACGIH Threshold Limit Values (TLV) Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL CA QC OEL	:	Canada. British Columbia OEL Québec. Regulation respecting occupational health and safe- ty, Schedule 1, Part 1: Permissible exposure values for air- borne contaminants
ACGIH / TWA CA AB OEL / TWA CA BC OEL / TWA CA QC OEL / TWAEV	:	8-hour, time-weighted average 8-hour Occupational exposure limit 8-hour time weighted average Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemi-

SAFETY DATA SHEET according to the Hazardous Products Regulations



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
3.1	09/30/2023	717974-00016	Date of first issue: 06/01/2016

cal Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Povision Data		00/20/2022

Revision Date	: 09/30/2023
Date format	: mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8